| Bioactivity | L-NBDNJ, a glycomimetic, is an antivirulence agent. L-NBDNJ interferes with the expression of proteins regulating cytoskeleton assembly and organization of the host cell. L-NBDNJ has anti-inflammatory and anti-infective effects in models of cystic fibrosis (CF) lung disease infection[1]. |
| Invitro | L-NBDNJ 是一种糖模拟物，是一种抗毒力剂。L-NBDNJ 会干扰调节宿主细胞骨架组装和组织的蛋白质的表达。L-NBDNJ 必须干扰参与宿主细胞骨架组装和组织的代谢途径，下调参与宿主反应的铜绿假单胞菌的主要毒力因子，并影响病原体对人体细胞的粘附[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> L-NBDNJ 相关抗体: |
| In Vivo | L-NBDNJ（10-100 mg/kg；口服管饲；每日；持续 6 天）在小鼠中表现出抗炎和抗感染作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C10H21NO4 |
| Molar Mass | 219.28 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Anna Esposito, et al. Assessing the Potential of N-Butyl-l-deoxynojirimycin (l-NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent. ACS Pharmacol. Transl. Sci. May 10, 2024. |